Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Nevo Stent Inhibits Tissue Proliferation Better Than Boston Sci’s Liberté

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson/Cordis' Nevo next-generation sirolimus-eluting coronary stent inhibits tissue proliferation better than Boston Scientific's Taxus Liberté paclitaxel-eluting stent at six months, according to data from the NEVO RES-Elution I study unveiled May 19 at the EuroPCR meeting in Barcelona
Advertisement

Related Content

J&J Temporarily Halts Nevo Stent Trial, Citing Needed Catheter Improvements
J&J Temporarily Halts Nevo Stent Trial, Citing Needed Catheter Improvements
EuroPCR In Brief
EuroPCR In Brief
J&J Appeals FDA "Not-Approvable" Letter For Sedasys Sedation System
J&J Appeals FDA "Not-Approvable" Letter For Sedasys Sedation System
J&J Appeals FDA "Not-Approvable" Letter For Sedasys Sedation System
J&J Orthopedic, Surgical Sales Help Offset 12% Cordis Decline In 2008
Xience V / Promus Drug-Eluting Stent Is Off And Running On U.S. Market
Xience V / Promus Drug-Eluting Stent Is Off And Running On U.S. Market

Topics

Advertisement
UsernamePublicRestriction

Register

MT027478

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel